LPCN · XBRL financial data

Lipocine financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LPCN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	(3,122)	216*	7,617	90	0*	3,491*	94	623	115	1,145*	119	190
Research and development	2,879	1,675*	2,819	1,875	1,585	1,073*	1,062	2,137	2,708	2,678*	2,764	2,041
General and administrative	1,043	1,135*	1,576	1,507	1,045	873*	1,122	890	768	983*	1,204	991
Total operating expenses	3,921	2,810*	4,395	3,382	2,630	1,946*	2,184	3,027	3,476	3,661*	3,969	3,032
Operating income (loss)	(7,043)	(2,593)*	3,223	(3,293)	(2,630)	1,545*	(2,090)	(2,404)	(3,361)	(2,516)*	(3,849)	(2,842)
Interest income	318	299*	331	309	274	233*	226	199	174	146*	178	220
Income tax expense (benefit)	0*	1*	0	0	0*	0*	0	0*	0*	0*	—	0
Net income (loss)	(6,651)	(2,282)*	3,514	(3,069)	(2,219)	1,782*	(1,865)	(2,206)	(3,187)	(2,370)*	(3,672)	(2,623)
Earnings per share, basic USD per share	(1.26)	—	0.66	(0.57)	(0.41)	0.33*	(0.35)	(0.41)	(0.59)	(0.42)*	(0.54)	(0.32)
Earnings per share, diluted USD per share	(1.27)	—	0.66	(0.56)	(0.44)	0.32*	(0.35)	(0.41)	(0.59)	(0.35)*	(0.54)	(0.32)
Weighted average shares, basic thousands of shares	5,292	—	5,316	5,344	5,348	5,348*	5,349	5,352	5,413	5,679*	6,795	8,217
Weighted average shares, diluted thousands of shares	5,292	—	5,358	5,344	5,348	5,639*	5,349	5,352	5,413	6,708*	6,795	8,217

Fiscal quarters (LPCN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	4,073	4,772	3,081	5,553	3,743	6,206	3,355	6,044	3,901	5,206	5,016	4,979
Marketable securities	19,775	17,264	21,551	16,995	16,081	15,427	16,364	11,892	11,230	9,725	19,713	18,287
Prepaid and other current assets	594	773	583	297	589	568	429	363	684	788	285	179
Total current assets	24,614	22,861	25,315	22,909	20,504	22,322	20,326	18,420	15,930	16,878	25,245	23,737
Property and equipment, net	115	116	108	99	171	165	150	133	119	104	89	75
Total assets	24,752	23,001	25,447	23,032	20,698	22,511	20,500	18,577	16,073	17,006	25,358	23,835
Accounts payable	1,101	1,396	671	449	285	272	360	443	861	972	1,563	681
Accrued liabilities	1,140	1,218	761	1,233	1,292	921	619	686	750	1,236	645	1,067
Total current liabilities	2,241	2,632	1,490	1,824	1,581	1,513	1,300	1,449	1,931	2,528	2,528	2,068
Total liabilities	2,271	2,632	1,490	1,824	1,581	1,513	1,300	1,449	1,931	2,528	2,528	2,068
Accumulated deficit	(197,495)	(199,777)	(196,264)	(199,332)	(201,551)	(199,769)	(201,634)	(203,839)	(207,026)	(209,396)	(213,068)	(215,691)
Total stockholders' equity	22,482	20,369	23,956	21,208	19,117	20,998	19,200	17,128	14,142	14,477	22,830	21,767
Total liabilities and equity	24,752	23,001	25,447	23,032	20,698	22,511	20,500	18,577	16,073	17,006	25,358	23,835
Common shares outstanding (cover page) thousands of shares	5,316	5,316	5,348	5,348	5,348	5,350	5,350	5,419	5,552	7,300	8,244	8,244

Fiscal quarters (LPCN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6,651)	(2,282)*	3,514	(3,069)	(2,219)	1,782*	(1,865)	(2,206)	(3,187)	(2,370)*	(3,672)	(2,623)
Stock-based compensation	158	154*	99	102	108	99*	71	65	53	53*	65	58
Net cash from operating activities	(2,606)*	(2,022)*	2,408	(2,498)*	(2,833)*	1,702*	(1,969)	(1,886)*	(2,986)*	(2,920)*	(2,257)	(3,028)*
Purchases of property and equipment	0*	9*	—	—	—	10*	—	—	—	—	—	—
Net cash from investing activities	1,243*	2,727*	(4,090)	4,752*	1,022*	761*	(882)	4,500*	701*	1,572*	(9,904)	1,485*
Proceeds from issuing common stock	421*	(5)*	—	—	0*	0*	—	—	141*	2,653*	11,964	1,508*
Share repurchases	—	—	8	—	—	—	—	—	—	—	—	—
Net cash from financing activities	421*	(5)*	(8)	217*	0*	0*	—	—	141*	2,653*	11,971	1,508*
Net change in cash	(942)*	699*	(1,690)	2,472*	(1,810)*	2,463*	(2,851)	2,689*	(2,143)*	1,305*	(190)	(36)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Clearside Biomedical	6,801	201	(5,480)*	5.2M	1.2 quarters	Q3 FY25 10-QSep 30, 2025
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.